We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Hogan Lovells Advises the Shareholders Of Internis Pharmaceuticals on its Sale to Stada Arzneimittel

05 June 2015

London, 5 June 2015 - Hogan Lovells has advised the shareholders of UK-based Internis Pharmaceuticals on its sale to German pharmaceutical company Stada Arzneimittel for £49 million.

The sale included Internis Pharmaceuticals’ Fultium-D3 prescription medicine for treating vitamin D3 deficiency.

The Hogan Lovells team acting for Internis Pharmaceuticals shareholders was led by Ed Harris (partner) assisted by Ollie Vallee, Suzy Penney, Holly Hirst and Dan Won on the Corporate aspects; Paul Joukador, George Jenkins, Jane Summerfield and Oliver Wilson on Commercial aspects; Philip Harle and Christopher Hyde on Tax aspects and Kiran Khetia on Employee Benefit aspects.

Loading data